Drugs / 4P004
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05419856 | Aug 2022 → Oct 2023 | osteoarthritis, knee | 4Moving Biotech | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07225829 | Jun 2025 → Jul 2026 overdue | osteoarthritis, knee, synovitis | 4Moving Biotech | Recruiting | No outcome recorded |
Press releases naming this drug 8 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4P-004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05419856 ↗ |
| Route | Other | “single intraarticular administration in the knee joint” NCT05419856 ↗ |